An oral psoriasis drug 'Sotyktu' is becoming available for prescription at general hospitals.

According to industry sources, BMS Korea’s Sotyktu (deucravacitinib) has passed the drug committee (DC) of hospitals, including Seoul Asan Hospital, Severance Hospital, Konyang University Hospital, Soonchunghyang University Bucheon Hospital, Seoul National University Bundang Hospital, Soonchunghyang University Hospital Seoul, Ewha Womans University Medical Center, Chosun University Hospital, and Soonchunghyang University Cheonan Hospital.

Sotyktu is expanding its prescription areas after being listed for insurance reimbursement in April.

Sotyktu is the first TYK2 inhibitor appro